Intracellular signaling: Fleshing out the TGFβ pathway  by Padgett, Richard W.
R408 Dispatch
Intracellular signaling: Fleshing out the TGFβ pathway
Richard W. Padgett
Recent studies of the intracellular signaling pathway
initiated by ligands of the transforming growth factor β
(TGFβ) family have provided new insights into how the
receptors for such ligands phosphorylate their
substrates — the Smads — and how signaling specificity
is achieved. 
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Members of the transforming growth factor β (TGFβ)
family of signalling molecules are found in a wide variety
of, and perhaps all, multicellular animals and are involved
in many essential developmental processes. Not surpris-
ingly, some member of the superfamily has been found to
be present in most tissues that have been examined. In
the last few years, most of the effort in the study of how
TGFβ ligands function has been devoted to tracing the
signaling pathway from the plasma membrane to the
nucleus. This bore fruit with the important discovery of
the ‘Smads’, intracellular proteins that interact with, and
become phosphorylated, by TGFβ receptors, and then
translocate to the nucleus. Once in the nucleus, some
Smads bind DNA, interact with other transcription factors
and activate target genes. These studies on Smads have
given us a rudimentary understanding of the signaling
pathway from the ligand to the nucleus [1–3].
Three recent studies have expanded our understanding of
different aspects of TGFβ signaling. First, the crystal
structure has been determined of part of one of the two
subunits that make up the TGFβ receptor [4], allowing a
detailed examination of the transmembrane-signal trans-
duction mechanism. Second, a protein that acts as an
adaptor between the receptor and the Smads has been
identified, providing new insights into the cytoplasmic
events leading to Smad activation [5]. And third, the
examination of the developmental roles of the C. elegans
type I receptor, Sma-6, has provided in vivo genetic evi-
dence that different type I receptors can interact with a
single type II receptor [6].
Structure of a type I receptor kinase domain 
TGFβ signals are transduced across the plasma membrane
by two related serine/threonine kinases, known as type I
and type II receptors. In animals, this receptor family
appears to be unique — all other transmembrane receptor
kinases that have been identified phosphorylate tyrosine
residues. One might therefore expect this pathway to
function differently from their tyrosine kinase cousins and
use unique components, and use of the Smad proteins
mentioned above is one example of this.
Another novel feature of TGFβ signaling is the so-called
GS domain of the type I receptor. This domain is
phosphorylated by the constitutively active type II
receptor, once the two receptors are brought in contact
with each other upon ligand binding. Huse et al. [4] have
now determined the crystal structure of the unphospho-
rylated kinase domain of the TGFβ type I receptor in a
complex with the ‘FK606-binding protein’ FKBP12.
FKBP12 binds to the GS domain, protecting the phos-
phorylation sites and stabilizing the receptor in an inac-
tive conformation, which is maintained by interactions
between the GS domain and the amino-terminal lobe of
the kinase. The relevance of FKBP12 binding to the
type I receptor is controversial, but it was necessary for
the structure determination.
The GS domain is tightly folded into two 180° turns in the
space of seven residues, and is partially buried in the rest
of the protein. Although the phosphorylated form of the
receptor has not been examined structurally, it seems rea-
sonable that phosphorylation of the GS domain would
change its conformation and relieve its inhibitory effects
on the receptor’s kinase activity. The GS domain may not
be required just to inactivate the kinase — it may also
have an active role in stimulating the kinase. Evidence for
this has come from the observation that deletions of the
GS domain inactivate the receptor; this implies that a
phosphorylated GS domain may be required in the active
state [7]. Obviously, the structure of the activated form of
the receptor will be of considerable interest.
Amino-acid sequence alignment has shown that, with
regard to its kinase domain, the TGFβ receptor is most
closely related to the insulin receptor tyrosine kinase and
less related to other serine/threonine kinases. Not surpris-
ingly, the α helices of the C lobe of the TGFβ type I
receptor can be superimposed onto the equivalent helices
of the insulin receptor, with a better fit than when they are
superimposed upon protein kinase A, which contains a
serine/threonine kinase domain. The catalytic region of
the TGFβ type I receptor is thus more similar to tyrosine
kinases than serine/threonine kinases. TGFβ receptors
might be intermediates between tyrosine and serine
threonine kinases.
An adaptor protein for Smads
The Smads were first identified by genetic analysis in the
fruitfly Drosophila and nematode Caenorhabditis elegans —
their name derives from Mad (Drosophila) and sma
(C. elegans), the first genes found to encode members of the
family [3]. Subsequent cloning of vertebrate homologs of
these genes led to discoveries about their function, particu-
larly details of their biochemical properties [1–3]. The
Smads were found to fall into distinct subtypes with differ-
ent properties. Thus, the ‘receptor-associated’ Smads
(R-Smads) complex with the type I receptors; they are
phosphorylated by the receptor kinase on ligand activation,
form a complex with a ‘common’ Smad (Co-Smad) and
move into the nucleus (Figure 1). One question remaining
from this skeletal view of TGFβ signaling is whether there
are cytoplasmic anchors for the Smads. Now, in a very nice
study, Tsukazaki et al. [5] have identified a protein dubbed
‘Smad anchor for receptor activation’, or SARA for short,
which appears to be such an anchor. 
SARA was isolated in a screen for proteins that interact
with the carboxy-terminal, transcriptional activator
(MH2) domain of Smad2. The SARA protein has a so-
called ‘FYVE’ domain, which is a double zinc-finger
domain that is found in several otherwise unrelated pro-
teins. In some of these other proteins, the FYVE domain
has been shown to bind phosphatidylinositol-3-phosphate
(PI(3)P), and so it might mediate interactions between
the protein that contains it and membranes [5]. It seems
likely that the FYVE domain in SARA functions in this
manner, but further experimentation will be required to
confirm this hypothesis.
One obvious question is whether SARA really does act as a
cytoplasmic anchor for the Smads. SARA was found to bind
unphosphorylated Smad2, and to be released from this
complex when Smad2 is phosphorylated by the type I
receptor (the basal level of SARA phosphorylation remains
unchanged on activation of the pathway). It appears that
Smad2–Smad4 and Smad2–SARA complexes are mutually
exclusive. Removing the Smad-binding domain of SARA
did not significantly reduce its interaction with the receptor,
showing that this is Smad-independent. SARA probably
binds directly to Smads, as the bacterially expressed pro-
teins were found to bind to each other efficiently.
Phosphorylated forms of Smad were found not be bind effi-
ciently to the SARA Smad-binding domain. Further, SARA
was found to bind to TGFβ receptor complexes.
The model that emerges from these various observations is
as follows (Figure 1). SARA is directed by its FYVE
domain to the membrane, where TGFβ receptor
molecules are located. At the membrane, SARA binds
unphosphorylated Smad2, thereby concentrating this inter-
mediary signaling molecule in the vicinity of TGFβ recep-
tor molecules. The carboxyl terminus of SARA facilitates
more direct interactions with TGFβ receptor complexes;
on receptor activation following ligand binding, Smad2 is
phosphorylated and released from the SARA adaptor
protein, forming Smad2–Smad4 complexes that move from
the cytoplasm to the nucleus to activate target genes.
How specific are SARA–Smad interactions? Interestingly,
SARA was found to bind only to Smad2 or Smad3, and
not to the other Smads. Previous studies have shown that
pathways activated by different TGFβ family ligands use
different Smads to send signals, raising the possibility
that other pathways may use different SARA-like adaptor
proteins. Searches of genome sequence databases have
indeed provided evidence for the existence of other
SARA-like proteins in humans, but whether they really
function in the various TGFβ family signaling pathways
remains to be seen. As SARA interacts with the Smads
via its Smad-binding domain, and such domains are
present in the related proteins, this does however seem a
likely possibility.
Studies using HepG2 cells have shown that various mutant
derivatives of SARA can suppress transcriptional  induction
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Figure 1
A general model of the TGFβ signaling pathway. A ligand binds to the
type I and type II receptor chains, resulting in phosphorylation of the
GS domain of the type I receptor polypeptide. The membrane-
associated protein SARA binds to an R-Smad and subsequently
contacts the receptor, facilitating the R-Smad—receptor interaction.
This interaction then causes the R-Smad to become phosphorylated
and consequently released from SARA. The R-Smad then complexes
with a Co-Smad and translocates to the nucleus. In the nucleus, the
Smad complex interacts with a transcription cofactor and induces
transcription downstream genes.
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via the Smad2-regulated activin response element (ARE).
This is consistent with SARA having an important role in
TGFβ signaling, but in the absence of further genetic evi-
dence this issue remains open. Are there really specific
SARA proteins for each TGFβ pathway? Do SARA pro-
teins function in other pathways besides the TGFβ-acti-
vated one? Does SARA really have a critical role in the
pathway, or just a minor role? These questions can be
addressed by genetic analysis in mice or invertebrates. It is
interesting that Drosophila and C. elegans do have SARA
homologs. In C. elegans, the homology is throughout the
protein, except for the Smad-binding domain. As the only
TGFβ family ligands in C. elegans appear to be members of
the bone morphogenetic protein (BMP) family, one might
expect C. elegans SARA-like proteins to have a distinct
BMP-specific Smad-binding domain.
Origin of signaling specificity
Recent studies of TGFβ signaling in C. elegans have also
provided insights into receptor function and signaling
specificity. Two distinct TGFβ-like signaling pathways,
known as the ‘Sma/Mab’ and ‘dauer’ pathways, have been
characterized in C. elegans [3]. The pathways were defined
genetically: mutations of genes encoding different type I
receptors were found to have phenotypic effects that were
different subsets of the phenotype caused by mutations of
daf-4, which encodes a type II receptor. The inference
was that there are two pathways, each using a different
type I receptor which interacts with distinct Smads and
thereby activates different downstream targets [8]. 
The genetic results thus indicate that, in C. elegans,
distinct type I receptors confer specificity in TGFβ
signaling. Is this a common theme for other TGFβ
pathways in other organisms? The Drosophila type II
receptor, Punt, has been found to interact with different
type I receptors to mediate signaling by two TGFβ-family
ligands, activin and Decapentaplegic [9,10]. Previous
biochemical studies in tissue culture have shown that dif-
ferent type I receptors can interact with a single type II
receptor (Figure 2). These observations suggest that the
ability of a given type II receptor to interact with multiple
type receptors is an ancient property of TGFβ signaling.
Future issues
Crystal structures of the activated form of the TGFβ type
I receptor and the receptor–SARA–Smad complex are
likely to be important if we were are to understand this
system at a deeper level, but such structures are likely to
prove difficult to obtain. Such structures should provide
important insights into TGFβ signaling and provide a
foundation for drug design aimed at stimulating or inhibit-
ing the pathway. Because the discovery of SARA is very
recent, we know little about its importance in signaling
and whether there are distinct SARA-like proteins for each
receptor–Smad interaction. One also wonders whether
there are additional proteins in the Smad–SARA complex
— will SARA turn out to be part of a scaffolding complex?
Although there is more to be learned about the upstream
aspects of TGFβ signaling, a lot of effort is being devoted
to elucidating the interactions of TGFβ with other signal-
ing pathways, as well as on downstream events in the
nucleus. We have only a superficial view of what Smad
gets up to in the nucleus. How do the Smads turn over, so
as to turn off signaling after a suitable period of time? And
with whom do they interact? How do other pathways
intersect with TGFβ? There have been a number of
reports of interactions between TGFβ and other signaling
pathways: with the epidermal growth factor (EGF) and
hepatocyte growth factor (HGF) pathways via Smad phos-
phorylation [11,12]; with the interferon γ pathway via
induced transcription of the ‘anti-Smad’ Smad7 [13]; and
with the vitamin D pathway, as a result of Smad3 binding
to and enhancing the transcriptional activity the vitamin D
receptor [14]. Future studies of the TGFβ signaling path-
ways are bound to yield new surprises that integrate many
important cellular pathways.
Acknowledgements
Work in the lab is supported by grants from the NIH. I thank members of the
lab for critical reading of the manuscript.
Figure 2
A shared type II receptor can function in multiple pathways. In
C. elegans, the daf-4 gene encodes a type II receptor. The Daf-4 type
II receptor interacts with either of two different type I receptors, Sma-6
or Daf-1, depending on which ligand is bound. Each type I receptor
interacts with a specific set of Smads, which induce distinct
downstream genes, resulting in different biological outputs.
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